Washington, D.C. 20549





Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) December 1, 2016



(Exact name of registrant as specified in its charter)


British Columbia, Canada   000-54598   N/A
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)


332 E. Scott Street

Port Hueneme, California 93041

(Address of principal executive offices) (Zip Code)


(805) 488-2800 

(Registrant’s telephone number, including area code)


Not applicable. 

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


As previously announced in a Current Report on Form 8-K filed with the Securities and Exchange Commission on October 24, 2016, effective December 1, 2016, Dr. Gregory T. Baxter was appointed as the Executive Vice President of Corporate Development of Stellar Biotechnologies, Inc. (the “Company”). As a result of and simultaneously with his appointment to the Company’s management team, Dr. Baxter, an independent member of the Company’s Board of Directors (the “Board”) resigned from the Board on December 1, 2016, effective immediately.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Stellar Biotechnologies, Inc.
Date: December 7, 2016 By: /s/ Kathi Niffenegger  
  Name:   Kathi Niffenegger  
  Title: Chief Financial Officer